Henry Stusnick
RA Capital Management

Henry Stusnick is an Analyst on the Investment Team at RA Capital Management. Henry works on both public and private investments and serves as a Board Director for Kinaset Therapeutics, as well as a Board observer for Ambros Therapeutics and Sparrow Pharmaceuticals. He previously served as a Board Observer for Bluejay Therapeutics (acquired by Mirum Pharmaceuticals) and SpyGlass Pharmaceuticals (NASDAQ: SGP). Prior to joining RA Capital, Henry worked as an Investment Banker at SVB Leerink (now Leerink Partners), advising biopharma companies on financing and strategic transactions. Henry received a BA in Biology and Economics from Dartmouth College.